Other Long Term Assets - Obio Technology Shanghai Corp Ltd (SSE:688238) - Alpha Spread
O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 4.05 CNY 4.38% Market Closed
Market Cap: 2.6B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Obio Technology Shanghai Corp Ltd
Other Long-Term Assets Peer Comparison

Comparables:
603259
300759
2269
300347
1548

Competitive Other Long-Term Assets Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Other Long-Term Assets
ÂĄ88m
CAGR 3-Years
11%
CAGR 5-Years
38%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Other Long-Term Assets
ÂĄ2.4B
CAGR 3-Years
-15%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Other Long-Term Assets
ÂĄ953.7m
CAGR 3-Years
22%
CAGR 5-Years
28%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Other Long-Term Assets
ÂĄ548.8m
CAGR 3-Years
30%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Other Long-Term Assets
ÂĄ363.9m
CAGR 3-Years
24%
CAGR 5-Years
-24%
CAGR 10-Years
57%
Genscript Biotech Corp
HKEX:1548
Other Long-Term Assets
$172.1m
CAGR 3-Years
187%
CAGR 5-Years
38%
CAGR 10-Years
N/A

See Also

What is Obio Technology Shanghai Corp Ltd's Other Long-Term Assets?
Other Long-Term Assets
88m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Other Long-Term Assets amounts to 88m CNY.

What is Obio Technology Shanghai Corp Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
38%

Over the last year, the Other Long-Term Assets growth was -31%. The average annual Other Long-Term Assets growth rates for Obio Technology Shanghai Corp Ltd have been 11% over the past three years , 38% over the past five years .

Back to Top